Anti-Mouse CD8a Monoclonal Antibodies for Flow Cytometry

PA007499.r2b: Recombinant Anti-mouse CD8a Monoclonal Antibody (Clone: YTS 105.18), Rat IgG2b Kappa

Recombinant Rat IgG2b Monoclonal Antibody. 
Clone: YTS 105.18.
Isotype:  Rat IgG2b Kappa.
Source: The anti-mouse CD8a monoclonal antibody (clone: YTS 105.18) was produced in mammalian cells.
Conjugation: Non-conjugated.
Specificity/Sensitivity: The recombinant YTS 105.18 antibody specifically binds to the mouse CD8a protein.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F). 
Form of Antibody: 0.2 uM filtered solution, pH 7.4, containing 0.09% sodium azide.
Purity: >95% by SDS-PAGE under reducing conditions.

PA007499.h1Fs: Recombinant Anti-mouse CD8a Monoclonal Antibody (Clone: YTS 105.18), Human IgG1 Fc Silent Kappa

Recombinant Human IgG1 Monoclonal Antibody with Fc silent mutation. 
Clone: YTS 105.18.
Isotype: Human IgG1 kappa.
Source: The anti-mouse CD8a monoclonal antibody (clone: YTS 105.18) was produced in mammalian cells.
Conjugation: Non-conjugated.
Specificity/Sensitivity: The recombinant YTS 105.18 antibody specifically binds to mouse CD8a protein.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F). 
Form of Antibody: 0.2 uM filtered solution, pH 7.4, containing 0.09% sodium azide.
Purity: >95% by SDS-PAGE under reducing conditions.

Shipping: The YTS 105.18 antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 
12 months from date of receipt, 2 to 8°C as supplied. Do not freeze it.

Background

The rat anti-mouse CD8a monoclonal antibody YTS 105.18 (rat IgG2b kappa) reacts with the mouse CD8a protein (T-cell surface glycoprotein CD8 alpha chain) encoded by the mouse CD8A gene that encodes the CD8a chain of the dimeric CD8 protein. The mouse CD8 protein is primarily responsible for cell-mediated immune defense and T-cell development. CD8A has been widely reported as a potential prognosis and diagnostic marker for several diseases, such as inflammatory disorders and tumors. YTS 105.18 is a rat IgG2b anti-CD8a monoclonal antibody that does not deplete CD8+ T-cells in vivo and is widely used for the blockade of CD8+ T-cell activity in mice. Inoculation of mice with YTS 105.18 induces tolerance to zenograft transplantation and reduces insulin-dependent diabetes mellitus (IDDM) in NOD mice.

Some suppliers and researchers state that YTS 105.18 is a rat IgG2a monoclonal antibody. Its sequence of the heavy chain indicates that it is a rat IgG2b antibody.

References of anti-mouse CD8a antibody (YTS 105.18)

IFNγ PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy.
Gibson, H. M., et al. (2018). Cancer Res. 2018 Oct 1;78(19):5706-5717. doi: 10.1158/0008-5472.CAN-18-0253. PMID: 30115693
Efforts to label CD8-specific full-length mAbs (clones 2.43 and non-depleting YTS-105.18) resulted in depletion of the target cell population and tracer accumulation in the kidneys with lack of secondary lymphoid tissue detection (data not shown) despite detection of CD8+ tumor infiltrates by flow cytometry and IHC (Fig. 6E-F). We tested the ability of TUBO tumor cells to retain IFN-γ: 89Zr-anti-IFN-γ complexes in vitro and find maximal binding when TUBO cells are pre-incubated with IFN-γ, supporting the working hypothesis that localized imaging is due to detection of IFN-γ associated with its receptor. Tumor-localized 89Zr-anti-IFN-γ tracer uptake inversely correlated with tumor growth rate (Fig. 6B and Supplementary Fig. 7, r=−0.64, 95% CI: (−0.90,−0.06); p=0.034), suggesting IFN-γ PET is an indicator of the effects of ITx on these tumors. IFN-γ PET of vaccinated tumors displayed a nearly two-fold higher uptake of 89Zr-anti-IFN-γ (8.37 ± 0.35% ID/g, n=4) vs. control (4.63 ± 0.47% ID/g, n=3, p=0.001), indicating infiltration of functional anti-tumor T cells (Fig. 4B and Supplementary Fig. 6A). A nearly two-fold increase in tumor uptake was observed in vaccinated (Vx: 10.07 ± 1.50% ID/g, n=6) versus control mice (Ctrl: 5.97 ± 0.61% ID/g, n=6, p=0.0001).
Tags: activity of YTS 105.18 mAb; function of YTS 105.18 antibody

Tolerance induction to human stem cell transplants with extension to their differentiated progeny.
Lui, K. O., et al. (2014). Nat Commun. 2014 Dec 1;5:5629. doi: 10.1038/ncomms6629. PMID: 25434740
Non-depleting mAb specific for CD4 (1 mg, clone YTS 177.9) and CD8 antibody (1 mg, clone YTS 105.18) were injected intraperitoneally (i.p.) on days 0, 2 and 4 post transplantation of murine ESC-derived EBs. Similarly, non-depleting mAb specific for CD4 (1 mg, clone YTS 177.9), CD8 antibody (1 mg, clone YTS 105.18) and CD40L (1 mg, clone MR1) were injected i.p. on days 0, 2, 4 and 6 after transplantation of hESCs, hiPSCs, hESC-derived neural cells or ECs. The PI −DIR +Tra-1-60 − nestin +neurofilament + human neural progenitor cells were transplanted under the kidney capsule of CD-1 mice following three injections of anti-CD4, -CD8 and -CD40L mAbs within the first week post transplantation and graft acceptance was monitored at day 30, 90 and 180 post transplantation. The PI −Tra-1-60 −CD31 +CD144 +eNOS + hESC-ECs were transplanted subcutaneously (s.c.) into CD-1 mice following three injections of anti-CD4, -CD8 and -CD40L mAbs within the first week post transplantation and graft acceptance was monitored at day 30 and 90 post transplantation. In the antigen specificity study, tolerized mice were transplanted with a second graft 3 months after the primary grafts had been transplanted.
Tags: in vivo study of YTS 105.18 antibody; YTS 105.18 antibody

Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance.
Kendal, A. R., et al. (2011). J Exp Med. 2011 Sep 26;208(10):2043-2053. doi: 10.1084/jem.20110767. PMID: 21875958
Tolerance across MHC and multiple minor histocompatibility barriers was achieved using three doses of 1 mg anti-CD4 (YTS 177.9), anti-CD8 antibody (YTS 105.18), and anti-CD154 (MR1) nondepleting mAbs over 7 d. YTH655 was prepared in house via purification of integra supernatant. An anti–dog rat IgG2b mAb (YKIX 337.217.1) prepared under the same conditions was used in all in vivo experiments as an isotype control mAb. Unless otherwise stated, Foxp3+hCD2+ T cell ablation was achieved using seven daily doses of 250 µg of rat IgG2b anti–human CD2 mAb (YTH655). Adoptive cell transfer was achieved by tail vein injection of an appropriate volume of washed cell suspension in sterile 1× PBS. 1 mg anti-hCD2 mAb (YTH655) or isotype control mAb per mouse was added to the cell suspension immediately before intravenous infusion.
Tags: YTS 105.18 antibody for animal model; YTS 105.18 antibody for cancer research

Biomarkers of transplantation tolerance: more hopeful than helpful?.
Cobbold, S. P., et al. (2011). Front Immunol. 2011 Apr 6;2:9. doi: 10.3389/fimmu.2011.00009. PMID: 22566800
B10.BR grafted CBA/Ca recipients were given the CD4 plus CD8 (clone YTS 105.18.10) antibodies (Qin et al., 1990). Recipients in the tolerant groups were given 3 × 1 mg each, on days −1, +1, and +3 relative to their first grafts, of non-depleting monoclonal antibodies (Figure 1). A1.RAG1 −/− recipients were given CD4 (clone YTS 177.9.6) antibody alone (Cobbold et al., 2004), B10.BR grafted CBA/Ca recipients were given the CD4 plus CD8 (clone YTS 105.18.10) antibodies (Qin et al., 1990), and CBA/Ca recipients of C57BL/6 skin were given a cocktail of CD4 plus CD8 plus CD154 (CD40L; clone MR1) antibodies (Daley et al., 2008). Tail skin was grafted on the lateral thoracic flank of recipient mice as previously described (Qin et al., 1990). Control recipients received either allogeneic or syngeneic tail skin grafts without antibody treatment.
Tags: YTS 105.18 antibody for flow cytometry; YTS 105.18 antibody for mouse tumor model

Type 1 Diabetes Development Requires Both CD4+ and CD8+ T cells and Can Be Reversed by Non-Depleting Antibodies Targeting Both T Cell Populations.
Phillips, J. M., et al. (2009). Rev Diabet Stud. 2009 Aug 10;6(2):97-103. doi: 10.1900/RDS.2009.6.97. PMID: 19806239
When this antibody was used in combination with the IgG2a anti-CD8α antibody, YTS105, CD8 + T cells were not depleted, but were functionally inactivated. Female NOD mice were tested for diabetes onset and once tested positively they were administered a combination of two non-depleting antibodies, an anti-CD4 and an anti-CD8α. In Figure 4, it can be seen that the combination therapy was able to reverse diabetes onset. Antibodies (2 mg of MAC 219, or 1 mg each of YTS 177 and YTS 105) were given i.p. every other day for 2 weeks. These antibodies have previously been used in combination to induce alloantigen-specific tolerance of skin, cardiac and bone marrow allografts.
Tags: YTS 105.18 mAb; YTS 105.18 mAb for flow cytometry

For more references about anti-mouse CD8a antibody (YTS 105.18), please contact our scientific support team with message@sydlabs.com.

Syd Labs provides the following recombinant anti-human CD8a monoclonal antibodies:
In vivo grade recombinant anti-human CD8a antibodies (clone OKT8)
Recombinant anti-human CD8a antibodies (clone OKT8) for flow cytometry

Syd Labs provides the following recombinant anti-mouse CD8a monoclonal antibodies:
In vivo grade recombinant anti-mouse CD8a antibodies (clone 2.43)
In vivo grade recombinant anti-mouse CD8a antibodies (clone YTS 169.4)
In vivo grade recombinant anti-mouse CD8a antibodies (clone YTS 105.18)

Syd Labs provides the following recombinant anti-mouse CD8b monoclonal antibodies:
In vivo grade recombinant anti-mouse CD8b antibodies (clone YTS 156.7)